Cytokinetics (CYTK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CYTK Stock Rises as Enrollment Begins in Phase II Heart Failure Study
Cytokinetics stock up as the company initiates patient enrollment in its mid-stage study of pipeline candidate, CK-586, for treating heart failure patients.
Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst
Stifel initiated coverage on Cytokinetics Incorporated CYTK, noting the company's catalyst rich one to two years.
Cytokinetics Aligns For U.S. Launch Amid HCM Market Evolution
Cytokinetics is advancing aficamten, a potential competitor to Camzyos, targeting hypertrophic cardiomyopathy (HCM). Strategic licensing deals with Sanofi and Bayer secure resources and focus US commercialization. Clinical trials aim to expand aficamten's utility, including first-line and pediatric indications.
Why Cytokinetics Stock Was a Nearly 5% Winner Today
California-based biotech Cytokinetcs (CYTK 4.56%) finished the trading week in style, as its stock price outperformed many other titles by rising nearly 5% on Friday. News of a fresh licensing deal in a key market abroad was the catalyst for the increase, which well exceeded the slightly over 1% gain of the S&P 500 index.
Why Is Cytokinetics (CYTK) Down 9.7% Since Last Earnings Report?
Cytokinetics (CYTK) reported earnings 30 days ago. What's next for the stock?
Cytokinetics Initiates Confirmatory Study on Heart Failure Drug
CYTK opens enrollment in the phase III COMET-HF study on omecamtiv mecarbil in patients with symptomatic heart failure with severely reduced ejection fraction.
FDA Accepts Cytokinetics' Application for Cardiovascular Drug
CYTK's NDA is seeking approval for the lead pipeline candidate, aficamten, which the FDA accepted and assigned a target action date of Sept. 26, 2025.
Bayer Acquires Rights for Cardiovascular Drug From CYTK in Japan
BAYRY enters into a collaboration and license agreement with Cytokinetics for the exclusive development and commercialization of aficamten in Japan.
Bayer acquires rights to Cytokinetics' heart drug in Japan
Bayer on Tuesday struck a collaboration deal with U.S. biotech firm Cytokinetics to acquire certain rights in Japan to an experimental heart drug, as the German group strengthens its cardiovascular business with smaller deals.
Cytokinetics, Incorporated (CYTK) Q3 2024 Earnings Call Transcript
Cytokinetics, Incorporated (CYTK) Q3 2024 Earnings Call Transcript
Cytokinetics (CYTK) Reports Q3 Loss, Lags Revenue Estimates
Cytokinetics (CYTK) came out with a quarterly loss of $1.36 per share versus the Zacks Consensus Estimate of a loss of $1.27. This compares to loss of $1.35 per share a year ago.
